Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Core Insights - Thermo Fisher Scientific Inc. reported first-quarter 2025 adjusted earnings per share (EPS) of $5.15, exceeding the Zacks Consensus Estimate by 1% and reflecting a year-over-year increase of 0.8% [1] - The company's GAAP EPS was $3.98, marking a 15% increase year over year [1] - Following the earnings announcement, shares of Thermo Fisher rose 1.7% in pre-market trading [2] Revenue Performance - Total revenues for the quarter reached $10.36 billion, a 0.2% increase year over year, surpassing the Zacks Consensus Estimate by 1.1% [3] - Organic revenues increased by 1% year over year [3] Segment Analysis - Life Sciences Solutions segment (22.6% of total revenues) saw revenues increase by 2.4% year over year to $2.34 billion, exceeding estimates [4] - Analytical Instruments segment (16.6%) reported a 1.8% year-over-year increase in revenues to $1.72 billion, which fell short of estimates [5] - Specialty Diagnostics segment (11.1%) experienced a 3.5% year-over-year revenue increase to $1.15 billion, surpassing predictions [6] - Laboratory Products and Biopharma Services segment (54.4%) saw a decline of 1.4% year over year, with revenues at $5.64 billion, slightly below estimates [7] Margin Performance - Gross margin for the first quarter was 41.6%, contracting by 5 basis points year over year due to a 0.3% rise in the cost of revenues [8] - Selling, general and administrative expenses decreased by 0.6% to $1.72 billion, while research and development expenses increased by 3.3% to $342 million [8] - Adjusted operating margin was 21.7%, reflecting a contraction of 2 basis points [8] Financial Position - At the end of Q1 2025, cash and cash equivalents and short-term investments totaled $5.95 billion, up from $5.57 billion at the end of Q4 2024 [9] - Net cash from operating activities was $723 million, down from $1.25 billion a year ago [10] - The company has a consistent dividend-paying history, with a five-year annualized dividend growth of 15.10% [10] Strategic Developments - During the first quarter, Thermo Fisher launched several innovative products, including the Thermo Scientific Vulcan Automated Lab and Olink Reveal proteomics kits, contributing to commercial success [12] - The company announced an agreement to acquire Solventum's Purification & Filtration Business for $4.1 billion in cash [12] Overall Assessment - Thermo Fisher's first-quarter results exceeded expectations in terms of earnings and revenues, with growth in most segments except for Laboratory Products and Biopharma Services [11] - The contraction in margins was noted as a concern, and the company is expected to provide guidance for 2025 in an upcoming earnings call [11]

Core Viewpoint - Thermo Fisher Scientific Inc. reported strong first-quarter 2025 results, with adjusted earnings per share of $5.15, surpassing analyst expectations of $5.10, and quarterly sales of $10.36 billion, slightly above the consensus estimate of $10.23 billion [1][2] Financial Performance - Adjusted operating income for Q1 2025 was $2.27 billion, a slight decrease from $2.28 billion in the same quarter last year [3] - Adjusted operating margin was 21.9%, down from 22% in Q1 2024 [3] - Organic revenue growth was recorded at 1% [1] Segment Performance - Life Sciences Solutions Segment revenue increased by 2.5% year over year to $2.34 billion [3] - Analytical Instruments Segment sales rose by 1.8% to $1.72 billion [3] - Specialty Diagnostics Segment revenues grew by 3.5% to $1.15 billion [4] - Laboratory Products and Biopharma Services segment sales decreased by 1.5% to $5.64 billion [4] Strategic Developments - The company announced an agreement to acquire Solventum's SOLV Purification & Filtration business for approximately $4.1 billion in cash, which focuses on purification and filtration technologies for biologics and medical technologies [4] Market Reaction - Following the earnings report, Thermo Fisher's stock price increased by 4.23%, reaching $453.10 [5]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $10.36 billion, with adjusted operating income of $2.27 billion and an adjusted operating margin of 21.9% [10][11] - Adjusted EPS grew by 1% to $5.15 per share, while GAAP EPS increased by 15% to $3.98 [36] - Organic revenue growth was approximately $100 million or 1% ahead of expectations, with reported revenue flat year over year [35][37] Performance by Business Lines - Life Science Solutions reported a 2% increase in revenue, driven by bioproduction, but adjusted operating income decreased by 1% [43][44] - Analytical Instruments saw a 2% revenue growth, led by electron microscopy, with adjusted operating income flat year over year [45][46] - Specialty Diagnostics grew by 3% in revenue, with adjusted operating income increasing by 3% [46][47] - Laboratory Products and Biopharma Services experienced a 1% decrease in both reported and organic revenue, primarily due to the runoff of pandemic-related revenue [48] Market Data and Key Metrics Changes - North America revenue was flat year over year, while Europe and Asia Pacific grew low single digits, with China declining mid-single digits [38] - Academic and government revenue declined low single digits due to macro conditions in the U.S. and China [12][13] Company Strategy and Development Direction - The company’s growth strategy focuses on high-impact innovation, trusted partner status with customers, and a strong commercial engine [14][18] - Recent product launches include the Thermo Scientific Vulcan automated lab and the next-generation Thermo Scientific Transcend platform, enhancing market leadership [15][17] - The company is actively managing its supply chain to mitigate tariff impacts and is investing $2 billion in U.S. manufacturing and R&D [31][41] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a more uncertain macro environment but emphasized strong execution and customer success [8][9] - Updated guidance for 2025 includes revenue expectations of $43.3 billion to $44.2 billion and adjusted EPS in the range of $21.76 to $22.84 [26][61] - Management remains optimistic about long-term growth despite current challenges, citing strong demand for healthcare and scientific breakthroughs [87][89] Other Important Information - The company repurchased $1 billion of shares and increased its dividend by 10% during the quarter [24] - The acquisition of SOVENTUM's purification and filtration business for $4.1 billion is expected to close by the end of 2025 [22][23] Q&A Session Summary Question: Guidance methodology in light of market uncertainty - Management acknowledged the dynamic nature of the macro environment and emphasized their agility in navigating risks and capitalizing on opportunities [72][76] Question: Long-term growth outlook for the tools market - Management expressed optimism about long-term growth driven by healthcare demand and scientific advancements, despite potential short-term challenges [84][87] Question: Changes in order behavior due to tariffs - Management noted that there has not been a significant pull forward in orders due to the short notice of tariff announcements [93][94] Question: Flexibility in manufacturing - Management highlighted the company's robust manufacturing capabilities and flexibility across different product types, which positions them well to adapt to changes [96][101] Question: Impact of pharmacy tariffs - Management indicated ongoing discussions with pharmaceutical customers regarding tariffs and emphasized the importance of U.S. manufacturing capabilities [105][106] Question: Breakdown of policy-related guidance reduction - Management clarified that $200 million of the guidance reduction was due to canceled vaccine-related studies, with the remainder reflecting softer academic and government spending [114][115] Question: Pricing assumptions in light of tariffs - Management stated that they are implementing appropriate pricing actions to mitigate tariff impacts, expecting a slight increase in pricing across the portfolio [120][121]

Core Insights - Thermo Fisher Scientific reported revenue of $10.36 billion for the quarter ended March 2025, reflecting a year-over-year increase of 0.2% and an EPS of $5.15, up from $5.11 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $10.25 billion by 1.11%, while the EPS surpassed the consensus estimate of $5.10 by 0.98% [1] Revenue Performance - Organic revenue growth was 1%, compared to the average estimate of 0.2% from five analysts [4] - Life Sciences Solutions revenue was $2.34 billion, exceeding the estimated $2.28 billion, representing a year-over-year increase of 2.5% [4] - Analytical Instruments revenue was $1.72 billion, slightly below the estimated $1.73 billion, with a year-over-year increase of 1.8% [4] - Laboratory Products and Biopharma Services revenue was $5.64 billion, slightly above the estimated $5.61 billion, but showed a year-over-year decline of 1.5% [4] - Specialty Diagnostics revenue was $1.15 billion, surpassing the estimated $1.10 billion, with a year-over-year increase of 3.5% [4] - Revenues from Eliminations were reported at -$482 million, worse than the average estimate of -$449.31 million, but showed a year-over-year improvement of 4.8% [4] Stock Performance - Thermo Fisher's shares have returned -15.5% over the past month, compared to a -6.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Company Performance - Thermo Fisher Scientific reported quarterly earnings of $5.15 per share, exceeding the Zacks Consensus Estimate of $5.10 per share, and showing a slight increase from $5.11 per share a year ago [1] - The company achieved revenues of $10.36 billion for the quarter, surpassing the Zacks Consensus Estimate by 1.11%, and showing a marginal increase from $10.35 billion year-over-year [3] - Over the last four quarters, Thermo Fisher has consistently surpassed consensus EPS estimates four times and revenue estimates three times [2][3] Market Outlook - The stock has underperformed, losing approximately 16.4% since the beginning of the year, compared to a decline of 10.1% for the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $5.56, with expected revenues of $10.78 billion, and for the current fiscal year, the EPS estimate is $23.17 on revenues of $43.82 billion [8] Industry Context - The Medical - Instruments industry, to which Thermo Fisher belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [6]

导读： 近期，关税战愈演愈烈，在此背景下，我们特别盘点美国十家科学仪器企业在华的发展布局，以期洞察未来趋势。 他还着重表示，珀金埃尔默太仓工厂扩建项目已完成，新的现代化生产设施和运营平台将在现有的太仓基地附近投产，面积扩大近四倍，并将 逐步实现全品类产线转移。这将进一步提升公司在中国市场的生产和运营规模，更好地服务中国客户。珀金埃尔默将持续关注中国市场与客户 需求的变化，不断推出适应中国市场的产品和解决方案，为中国客户提供创新技术和专业服务。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2 0 2 5年2月2 8日，胡润研究院发布《2 0 2 4在中国的美国企业特别报告》，报告共收集了7 0家标普5 0 0成分股美国企业的数据，这些企业均披露 了其在中国市场的营收数据。 样本企业在全球市场的收入总额超过2 . 5万亿美元，相当于美国2 0 2 3年GDP总和的9%。报告中不仅提及了苹 果、特斯拉、沃尔玛等知名企业，还特别关注了珀金埃尔默、r e v v it y等科学仪器领域的美国品牌。 回顾历史，自上世纪8 0年代前后，珀金埃 ...

Core Viewpoint - Analysts project that Thermo Fisher Scientific (TMO) will report quarterly earnings of $5.10 per share, reflecting a 0.2% decline year over year, with revenues expected to reach $10.25 billion, down 0.9% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating a reassessment by covering analysts [1][2]. - Revisions to earnings estimates are crucial for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [2]. Revenue Projections - Analysts forecast 'Revenues- Laboratory Products and Biopharma Services' to reach $5.61 billion, indicating a decline of 2.1% from the prior-year quarter [4]. - 'Revenues- Specialty Diagnostics' is expected to be $1.10 billion, reflecting a decrease of 0.5% year over year [4]. - 'Revenues- Life Sciences Solutions' is projected at $2.28 billion, showing a year-over-year change of -0.3% [4]. Geographic Revenue Estimates - 'Revenues- Analytical Instruments' is expected to reach $1.73 billion, suggesting a year-over-year increase of 2.5% [5]. - 'Geographic Revenues- Customer Location- North America' is projected at $5.43 billion, indicating a decline of 1.7% year over year [5]. - 'Geographic Revenues- Customer Location- Asia-Pacific' is estimated at $1.88 billion, reflecting a growth of 0.8% [5]. - 'Geographic Revenues- Customer Location- Other regions' is expected to reach $368.42 million, indicating a year-over-year increase of 6.5% [6]. - 'Geographic Revenues- Customer Location- Europe' is projected at $2.60 billion, reflecting a decrease of 0.7% from the year-ago quarter [6]. Stock Performance - Shares of Thermo Fisher have shown a return of -15.7% over the past month, compared to a -6.3% change in the Zacks S&P 500 composite [6].

Core Viewpoint - Thermo Fisher Scientific Inc. is expected to report first-quarter 2025 results on April 23, with a consensus estimate for revenues at $10.25 billion, indicating a 0.9% decline year-over-year, and earnings per share (EPS) at $5.10, reflecting a 0.2% decline from the previous year [1][2]. Revenue Estimates - The Zacks Consensus Estimate for Thermo Fisher's first-quarter revenues is $10.25 billion, suggesting a 0.9% decline from the prior-year quarter [1]. - The Analytical Instruments segment is projected to generate $1.78 billion in revenues, indicating a 5.8% growth year-over-year [5]. - The Life-Science Solutions business is expected to report $2.16 billion in revenues, reflecting a 5.4% decline year-over-year [8]. - The Specialty Diagnostics segment is anticipated to generate $1.09 billion in revenues, suggesting a 1.6% decline year-over-year [10]. - The Laboratory Products and Services segment is expected to report revenues of $5.65 billion, down 1.2% year-over-year [12]. Factors Influencing Performance - Strong sales are anticipated in the Analytical Instruments segment, driven by electron microscopy and chromatography and mass spectrometry businesses, including the launch of the Invitrogen EVOS S1000 Spatial Imaging System [3]. - The Life-Science Solutions segment is likely to benefit from sales growth in bioproduction and biosciences, with notable developments such as the Olink Explore Platform being selected for a major human proteomics study [6]. - The bioproduction business is expected to grow due to strong adoption in the pharma and biotech sectors, supported by the introduction of the Accelerator Drug Development solution [7]. - The Specialty Diagnostics segment is expected to gain from contributions in transplant diagnostics and immunodiagnostics, along with new registry launches [9]. - The Laboratory Products and Services segment is projected to see revenue increases due to the research and safety market, with new product launches aimed at semiconductor manufacturing [11]. Estimate Revision Trend - Estimates for Thermo Fisher's first-quarter earnings have decreased by 0.2% to $5.10 per share over the past 30 days [2].

Core Insights - The article emphasizes the importance of identifying good companies at bargain prices for long-term returns and dividends in various investing climates [1] Group 1 - Grant Gigliotti, the founder of Beat The Market Analyzer, has over 20 years of experience in active investing and focuses on value investing strategies similar to those of Warren Buffett [2] - The goal is to demonstrate how to purchase companies with strong fundamentals at significant discounts from their intrinsic value [2]